Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer.
Saved in:
| Title: | Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer. |
|---|---|
| Authors: | Ray-Coquard I; GINECO and Medical Oncology Department, Centre Léon Bérard, University Claude Bernard Lyon, Lyon, France., Cibula D; AGO and Oncogynecologic Center, Department of Obstetrics and Gynecology, General Faculty Hospital, Charles University of Prague, Prague, Czech Republic., Mirza MR; NSGO and Department of Oncology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark., Reuss A; AGO and Coordinating Center for Clinical Trials, Philipps-University of Marburg, Marburg, Germany., Ricci C; MITO and Division of Gynecologic Oncology, Department of Women and Children's Health and Public Health, Fondazione Policlinico Gemelli IRCCS, Rome, Italy., Colombo N; MaNGO and European Institute of Oncology and University of Milan Bicocca, Milan, Italy., Koch H; AGO Austria and Department of Obstetrics and Gynecology, Paracelsus Medical University, Salzburg, Austria., Goffin F; BGOG and CHU de Liège, University of Liège, Liège, Belgium., González-Martin A; GEICO and Medical Oncology Department, Clínica Universidad de Navarra, Madrid, Spain., Ottevanger PB; DGOG and Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands., Baumann K; AGO and Department of Gynecology, Klinikum der Stadt Ludwigshafen GmbH, Ludwigshafen, Germany., Bjørge L; NSGO and Department of Gynecology, Haukeland Universitetssykehus, Bergen, Norway.; Center for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway., Lesoin A; GINECO and Department of Gynecologic Cancer and Medical Oncology, Centre Oscar Lambret, Lille, France., Burges A; AGO and Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Germany., Rosenberg P; NSGO and Department of Oncology, University Hospital Linköping, Linköping, Sweden., Gropp-Meier M; AGO and Department of Gynecology and Obstetrics, Oberschwabenklinik, Krankenhaus St. Elisabeth, Ravensburg, Germany., Harrela M; NSGO and Department of Gynoncology and Gynecology and Obstetrics, Kymenlaakso Central Hospital, Kotka, Finland., Harter P; AGO and Department of Gynecology and Gynecologic Oncology, Kliniken Essen Mitte, Essen, Germany., Frenel JS; GINECO and Centre René Gauducheau, Institut de Cancerologie de l'Ouest, Saint Herblain, France., Minarik T; NSGO and National Institute of Oncology, Bratislava, Slovakia., Pisano C; MITO and Department of Uro-Gynecologic Oncology, Istituto Nazionale per Io Studio e la Cura dei Tumori 'Fondazione G. Pascale' IRCCS, Naples, Italy., Hasenburg A; AGO and Department of Obstetrics and Gynecology, University Medical Center, Mainz, Germany., Merger M; Oncology Medicine, Boehringer Ingelheim International GmbH, Biberach, Germany., du Bois A; AGO and Department of Gynecology and Gynecologic Oncology, Kliniken Essen Mitte, Essen, Germany. |
| Corporate Authors: | AGO Study Group-led GCIG/ENGOT Intergroup Consortium |
| Source: | International journal of cancer [Int J Cancer] 2020 Jan 15; Vol. 146 (2), pp. 439-448. Date of Electronic Publication: 2019 Sep 06. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley-Liss Country of Publication: United States NLM ID: 0042124 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0215 (Electronic) Linking ISSN: 00207136 NLM ISO Abbreviation: Int J Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1097-0215 |
|---|---|
| DOI: | 10.1002/ijc.32606 |
